
Oxford Biomedica acquires ABL Europe for €15m
Oxford Biomedica PLC, and Institut Mérieux have entered exclusive negotiations for the acquisition of ABL Europe Inc. This move is set to solidify...

Pierre Fabre Laboratories acquires Vertical Bio
The acquisition of Vertical Bio AG for an undisclosed amount of money allows Pierre Fabre Laboratories to...

UK publishes £2bn vision for engineering biology
Following extensive engagement with industry and stakeholders, the new "National Vision for Engineering Biology" lays out the government’s...

Pierre Fabre SA licences immunotherapy from Atara Biotherapeutics
Paris-based Pierre Fabre Laboratories SA already held a licence for the EU-approved tabelecleucel, an allogeneic T cell based second-line treatment...

BioLamina AB bags €19m funding for expansion
The tenth investement from Lauxera Capital Partners through its Lauxera Growth I fund will be usesd by the Swedish company to expand the development...

Breakthrough in COPD treatment
Sanofi's duplimab (Dupixent®) showcased notable efficacy in reducing exacerbations and enhancing lung function in its second positive Phase III...

Quotient Therapeutics kicks-off with US$50m financing
Flagship has confírmed to invest $50m in Quotient Therapeutics to advance development of a platform, licenced from Wellcome Sanger Institue...